Business Context and Reporting Period
This Form 8-K was filed by AgeX Therapeutics, Inc. (trading symbol: AGE) on September 15, 2020. The registrant is a Delaware corporation headquartered in Alameda, California, and is classified as an emerging growth company. The filing reports on a specific financing event occurring on the date of the report.
Key Financial Metrics and Obligations
The filing details a new debt obligation and associated equity issuance:
- New Debt: AgeX borrowed an additional $1.0 million under a Secured Convertible Facility Agreement with Juvenescence Limited.
- Repayment Date: The outstanding principal balance is due on March 30, 2023.
- Equity Issuance: In connection with the loan draw, AgeX agreed to issue warrants to purchase 588,235 shares of common stock.
- Warrant Terms: The exercise price is $0.85 per share. Issuance is contingent upon approval for listing by the NYSE American.
- Registration Status: The warrants are issued unregistered under Section 4(a)(2) and Regulation S exemptions.
The filing text does not provide clear values for total revenue, net profit, operating cash flow, gross margins, total debt balance, or liquidity ratios as of the reporting date.
Material Changes
The primary material change reported is the increase in indebtedness by $1.0 million and the creation of a new obligation to issue equity warrants. This transaction represents a drawdown on an existing credit facility originally dated March 30, 2020, and amended on July 21, 2020.
Outlook, Risks, and Contingencies
Default Provisions: The New Loan Agreement contains extensive Events of Default that could accelerate repayment prior to the March 2023 maturity date. These include failure to pay, insolvency, cross-defaults on other indebtedness exceeding $100,000, material adverse changes in financial condition, or loss of material collateral.
Forward-Looking Statements: The company includes standard disclaimers that actual results may differ materially from anticipated results due to various risk factors detailed in periodic SEC reports.
Contingencies: The issuance of the warrants is contingent upon NYSE American listing approval.
Investor Verification Checklist
- Verify the total outstanding principal balance under the Secured Convertible Facility Agreement following this $1.0 million draw.
- Confirm the status of the NYSE American listing approval for the 588,235 warrants.
- Review the company's current liquidity position to assess the ability to service the new debt and meet the March 2023 repayment date.
- Examine the "Risk Factors" section of the most recent 10-K or 10-Q for details on the specific risks associated with the Juvenescence facility.
- Check for any other indebtedness exceeding $100,000 that could trigger a cross-default event under the new agreement.